Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy (TRANSCEND-PILOT-017006)

ClinicalTrials.gov ID: NCT03483103

Public ClinicalTrials.gov record NCT03483103. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 2, 2026, 10:29 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2 Study of Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy in Adult Patients With Aggressive B-cell NHL (017006)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a Phase 2, open-label, multicenter study to determine the efficacy and safety of lisocabtagene maraleucel (JCAR017) in adult subjects who have relapsed from, or are refractory to, a single line of immunochemotherapy for aggressive B-cell non-Hodgkin lymphoma (NHL) and are ineligible for hematopoietic stem cell transplant (based on age, performance status, and/or comorbidities). Subjects will receive treatment with lisocabtagene maraleucel and will be followed for 2 years for safety, pharmacokinetics and biomarkers, disease status, quality of life, and survival.

Study identification

NCT ID
NCT03483103
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Enrollment
74 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jul 26, 2018
Primary completion
Sep 23, 2021
Completion
Nov 30, 2022
Last update posted
Dec 19, 2023

2018 – 2022

United States locations

U.S. sites
59
U.S. states
17
U.S. cities
22
Facility City State ZIP Site status
Banner MD Anderson Cancer Center Gilbert Arizona 85234
Local Institution - 0043 Gilbert Arizona 85234
Scripps Clinic La Jolla California 92037
UNC School of Medicine Los Angeles California 90095
University of California Los Angeles Los Angeles California 90095
Sutter Hematology and Oncology Sacramento California 95816
Sutter Medical Center Sacramento California 95816
Stanford Cancer Genetics Clinic Stanford California 94304
Local Institution - 0092 Stanford California 94305
Stanford Cancer Center Stanford California 94305
Local Institution - 0019 Atlanta Georgia 30342
The Blood and Marrow Transplant Group of Georgia Atlanta Georgia 30342
UNC School of Medicine Atlanta Georgia 30342
Local Institution - 0003 Chicago Illinois 60611
Northwestern University Feinberg School of Medicine Chicago Illinois 60611
Northwestern University Chicago Illinois 60611
Local Institution - 0016 Chicago Illinois 60637-1470
University of Chicago Chicago Illinois 60637-1470
University of Chicago Comprehensive Cancer Center Chicago Illinois 60637
Local Institution - 0046 Lexington Kentucky 40536
University of Kentucky/Markey Cancer Center Lexington Kentucky 40536
University of Kentucky Lexington Kentucky 40536
Local Institution - 0064 Louisville Kentucky 40241
Norton Cancer Institute - Brownsboro Louisville Kentucky 40241
UNC School of Medicine Louisville Kentucky 40241
Johns Hopkins Oncology Center Bunting Blaustein Building Baltimore Maryland 21231
Local Institution - 0009 Baltimore Maryland 21231
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Baltimore Maryland 21231
Local Institution - 0052 East Brunswick New Jersey 08816
Regional Cancer Care Associates East Brunswick New Jersey 08816
UNC School of Medicine East Brunswick New Jersey 08816
New York Oncology Hematology - Albany Cancer Center Albany New York 12208
New York Oncology Hematology P.C. Albany New York 12208
Local Institution - 0090 Rochester New York 14642
University of Rochester Cancer Center Rochester New York 14642
University of Rochester Medical Center Rochester New York 14642
Levine Cancer Institute Charlotte North Carolina 28204
Local Institution - 0021 Charlotte North Carolina 28204
Local Institution - 0039 Cincinnati Ohio 45236
Oncology Hematology Care, Inc. Cincinnati Ohio 45236
Oncology Hematology Care Cincinnati Ohio 45236
Local Institution - 0051 Portland Oregon 97213
Providence Cancer Center/Earle A. Chiles Res. Inst. Portland Oregon 97213
Providence Portland Medical Center Portland Oregon 97213
Local Institution - 0029 Pittsburgh Pennsylvania 15232
University of Pittsburgh Medical Center Hillman Cancer Center Pittsburgh Pennsylvania 15232
Greenville Health System - Cancer Institute - Faris Road Greenville South Carolina 29605
Greenville Health System Greenville South Carolina 29615
Local Institution - 0037 Greenville South Carolina 29615
Local Institution - 0083 Dallas Texas 75390-7208
UNC School of Medicine Dallas Texas 75390
Intermountain Healthcare - LDS Hospital Blood and Marrow Transplant Salt Lake City Utah 84143
Intermountain Healthcare - LDS Hospital Salt Lake City Utah 84143
Local Institution - 0074 Salt Lake City Utah 84143
Northwest Medical Specialties Tacoma Washington 98405
UNC School of Medicine Tacoma Washington 98405
Local Institution - 0055 Milwaukee Wisconsin 53226
Medical College of Wisconsin, Froedtert Hospital Milwaukee Wisconsin 53226
UNC School of Medicine Milwaukee Wisconsin 53226

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03483103, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Dec 19, 2023 · Synced Sep 2, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03483103 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →